Last updated on May 2008

Memantine for Agitation in Dementia


Brief description of study

We plan to evaluate the use of memantine in Alzheimer's disease to control agitation in the acute situation i.e under 12 weeks

Detailed Study Description

Agitation is a cause of morbidity and mortality in Alzheimer's due to distress and use of medication with side effects. Memantine has beed shown to be associated with less agitation and a recent study by forrest pharmaceuticals failed to recruit. We will perform a 12 week rct in 164 patients to test this hypothesis in a locality with no competing studies and in a clinical setting where the drug is not often used. We will compare with placebo and also use a rescue protocol derived from international best practice.

Clinical Study Identifier: NCT00371059

Contact Investigators or Research Sites near you

Start Over

CHRIS FOX, MBBSBscMsc

Oxleas Nhs Foundation Trust
Dartford, United Kingdom
  Connect »

CHRIS FOX, MBBSBscMsc

Kent and Medway NHS and Social Care Partnership Trust
Folkestone, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.